Pa. Appellate Court Upholds $76.6 Million Verdict in Risperdal Case



DOCUMENTS
  • Opinion


PHILADELPHIA — A Pennsylvania appellate court has upheld a $76.6 million plaintiffs’ verdict in a Risperdal male breast growth case, finding the evidence supported the jury’s award of damages to a 16-year-old boy and his mother.

In a Nov. 26 opinion, the Pennsylvania Superior Court further found that the plaintiffs’ failure-to-warn claim is not preempted by federal law because the defendant drug makers could have enhanced the Risperdal warning label via the Food and Drug Administration’s Changes Being Effected regulation.

A.Y. and his mother B.A.Y., both Tennessee residents, sued Janssen Pharmaceuticals Inc., Janssen Research & Development LLC, and Johnson & …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference

March 27, 2024 - Charleston, SC
The Charleston Place

MORE DETAILS



HarrisMartin's New Jersey Asbestos Litigation Conference

March 01, 2024 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS